Abstract
Allograft loss remains a severe clinical problem after kidney transplantation. The molecular mechanism of graft loss is a complex process involving T and/or B cell activation, inflammation responses, autophagy and apoptosis. Since these pathways are involved in immune responses in kidney transplant rejection, application of genetic interference to inhibit specific pathways could present an effective targeted gene therapy method. Recent studies have successfully attempted to use gene therapy to target the key molecules involved in immune responses during transplantation. This strategy has the potential to silence target genes associated with a variety of diseases, including those that trigger allograft loss following organ transplantation. In this review, we have discussed evidence of the clinical applicability of gene therapy in kidney transplantation based on known associations between kidney diseases and genes participating in the underlying mechanisms. The molecules contributing to immune responses and inflammatory injury are further highlighted as potential targets in future clinical therapy for renal transplantation.
Keywords: Gene therapy, Kidney transplantation, RNAi, siRNA, ESRD, Inferior vena cava.
Current Gene Therapy
Title:Gene Therapy in Kidney Transplantation: Evidence of Efficacy and Future Directions
Volume: 17 Issue: 6
Author(s): Jiawei Li, Guisheng Qi, Guowei Tu, Cheng Yang*Ruiming Rong*
Affiliation:
- Department of Urology, Zhongshan Hospital, Fudan University, Shanghai,China
- Department of Urology, Zhongshan Hospital, Fudan University, Shanghai,China
Keywords: Gene therapy, Kidney transplantation, RNAi, siRNA, ESRD, Inferior vena cava.
Abstract: Allograft loss remains a severe clinical problem after kidney transplantation. The molecular mechanism of graft loss is a complex process involving T and/or B cell activation, inflammation responses, autophagy and apoptosis. Since these pathways are involved in immune responses in kidney transplant rejection, application of genetic interference to inhibit specific pathways could present an effective targeted gene therapy method. Recent studies have successfully attempted to use gene therapy to target the key molecules involved in immune responses during transplantation. This strategy has the potential to silence target genes associated with a variety of diseases, including those that trigger allograft loss following organ transplantation. In this review, we have discussed evidence of the clinical applicability of gene therapy in kidney transplantation based on known associations between kidney diseases and genes participating in the underlying mechanisms. The molecules contributing to immune responses and inflammatory injury are further highlighted as potential targets in future clinical therapy for renal transplantation.
Export Options
About this article
Cite this article as:
Li Jiawei , Qi Guisheng , Tu Guowei , Yang Cheng *, Rong Ruiming *, Gene Therapy in Kidney Transplantation: Evidence of Efficacy and Future Directions, Current Gene Therapy 2017; 17 (6) . https://dx.doi.org/10.2174/1566523218666180214095606
DOI https://dx.doi.org/10.2174/1566523218666180214095606 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mitochondrial Tolerance to Drugs and Toxic Agents in Ageing and Disease
Current Drug Targets CPP-conjugated Anti-apoptotic Peptides as Therapeutic Tools of Ischemiareperfusion Injuries
Current Pharmaceutical Design Chemical Composition and Inhibitory Effects of Hypericum brasiliense and H. connatum on Prolyl Oligopeptidase and Acetylcholinesterase Activities
Medicinal Chemistry Mutagenic Approaches to Modifying Gap Junction Phenotype
Current Drug Targets Molecular Pathways Involved in the Early and Late Damage Induced by Testis Ischemia: Evidence for a Rational Pharmacological Modulation
Current Medicinal Chemistry Cytosolic Phospholipase A2 Inhibitors as Therapeutic Agents for Neural Cell Injury
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Can Life Before Birth Affect Health Ever After?
Current Women`s Health Reviews Current Management of Intermittent Claudication: The Role of Pharmacological and Nonpharmacological Symptom-Directed Therapies
Current Vascular Pharmacology Type 2 Transglutaminase in Neurodegenerative Diseases: The Mitochondrial Connection
Current Pharmaceutical Design LPA and its Analogs-Attractive Tools for Elucidation of LPA Biology and Drug Development
Current Medicinal Chemistry Therapy Against Ischemic Injury
Current Pharmaceutical Design A Critical Evaluation of Adenosine A2A Receptors as Potentially “Druggable” Targets in Huntingtons Disease
Current Pharmaceutical Design Dynamic Factors Controlling Targeting Nanocarriers to Vascular Endothelium
Current Drug Metabolism Diagnostic Value of HLA Typing in Pathogenesis of Cardiomyopathy
Cardiovascular & Hematological Disorders-Drug Targets Adenosine Neuromodulation and Traumatic Brain Injury
Current Neuropharmacology Beneficial Effects of Statins on Endothelial Dysfunction and Vascular Stiffness
Current Vascular Pharmacology Statins in Acute Coronary Syndromes
Current Pharmaceutical Design Energy Remodeling, Mitochondrial Disorder and Heart Failure
Current Pharmaceutical Design Anti-Allergic and Antioxidant Activity of 5-Hydroxy-3,6,7,3’,4’- Pentamethoxy Flavone Isolated from Leaves of Vitex negundo
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Contrast Echocardiography: An Update on Clinical Applications
Current Pharmaceutical Design